S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 ETFs for the Conservative Investor to Buy and Hold
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 ETFs for the Conservative Investor to Buy and Hold
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 ETFs for the Conservative Investor to Buy and Hold
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
3 ETFs for the Conservative Investor to Buy and Hold
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
A small venture capital player becomes a symbol in the fight over corporate diversity policies
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Forecast, Price & News

$1.45
-0.11 (-7.05%)
(As of 09/20/2023 ET)
Compare
Today's Range
$1.44
$1.58
50-Day Range
$1.45
$3.35
52-Week Range
$1.44
$8.25
Volume
707,604 shs
Average Volume
800,407 shs
Market Capitalization
$363.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.25

Lyell Immunopharma MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
331.0% Upside
$6.25 Price Target
Short Interest
Bearish
18.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.08) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

727th out of 961 stocks

Pharmaceutical Preparations Industry

341st out of 454 stocks


LYEL stock logo

About Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

LYEL Price History

LYEL Stock News Headlines

Lyell Immunopharma Shares Up 8% on Cellares Collaboration
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Why Shares of Lyell Immunopharma Jumped This Week
Lyell Immunopharma (LYEL) Receives a Buy from H.C. Wainwright
See More Headlines
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Company Calendar

Last Earnings
8/08/2023
Today
9/21/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LYEL
Fax
N/A
Employees
274
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.25
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+331.0%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-183,120,000.00
Net Margins
-432.13%
Pretax Margin
-432.13%

Debt

Sales & Book Value

Annual Sales
$84.68 million
Book Value
$3.34 per share

Miscellaneous

Free Float
190,781,000
Market Cap
$363.99 million
Optionable
Not Optionable
Beta
-1.38
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Richard D. Klausner M.D. (Age 71)
    Founder & Exec. Chairman
    Comp: $80k
  • Dr. Lynn Seely M.D. (Age 64)
    Ph.D., Pres, CEO & Director
    Comp: $430.69k
  • Mr. Charles W. Newton (Age 52)
    Chief Financial Officer
    Comp: $1.72M
  • Mr. Stephen J. Hill (Age 53)
    Chief Operating Officer
    Comp: $1.04M
  • Dr. Gary Lee Ph.D. (Age 46)
    Chief Scientific Officer
    Comp: $639.91k
  • Ms. Elizabeth Homans (Age 57)
    Consultant
    Comp: $1.99M
  • Prof. Stanley R. Riddell M.D.
    Founder & Scientific Advisor
  • Dr. Crystal L. Mackall M.D.
    Founder & Scientific Advisor
  • Nellie Dillery
    Director of Accounting
  • Ms. Ellen Rose
    Sr. VP of Communications & Investor Relations













LYEL Stock - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares.
View LYEL analyst ratings
or view top-rated stocks.

What is Lyell Immunopharma's stock price forecast for 2023?

4 brokerages have issued 1 year price targets for Lyell Immunopharma's shares. Their LYEL share price forecasts range from $4.00 to $9.00. On average, they predict the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 331.0% from the stock's current price.
View analysts price targets for LYEL
or view top-rated stocks among Wall Street analysts.

How have LYEL shares performed in 2023?

Lyell Immunopharma's stock was trading at $3.47 at the start of the year. Since then, LYEL shares have decreased by 58.2% and is now trading at $1.45.
View the best growth stocks for 2023 here
.

When is Lyell Immunopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our LYEL earnings forecast
.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.04. The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $3.31 million. Lyell Immunopharma had a negative net margin of 432.13% and a negative trailing twelve-month return on equity of 26.40%.

When did Lyell Immunopharma IPO?

(LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

What is Lyell Immunopharma's stock symbol?

Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."

Who are Lyell Immunopharma's major shareholders?

Lyell Immunopharma's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.21%), Foresite Capital Management IV LLC (3.86%), State Street Corp (2.46%), Geode Capital Management LLC (1.34%), Northern Trust Corp (0.57%) and Charles Schwab Investment Management Inc. (0.46%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends
.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyell Immunopharma's stock price today?

One share of LYEL stock can currently be purchased for approximately $1.45.

How much money does Lyell Immunopharma make?

Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $363.99 million and generates $84.68 million in revenue each year. The company earns $-183,120,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

How many employees does Lyell Immunopharma have?

The company employs 274 workers across the globe.

How can I contact Lyell Immunopharma?

The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com.

This page (NASDAQ:LYEL) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -